Apexigen, Inc. (APGN)
| Market Cap | 155.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.79M |
| Shares Out | 21.44M |
| EPS (ttm) | -1.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102,071 |
| Open | 7.49 |
| Previous Close | 7.62 |
| Day's Range | 6.93 - 7.71 |
| 52-Week Range | 5.11 - 31.35 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About APGN
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinica... [Read more...]
Financial Performance
Financial StatementsNews
Vintage Wine Estates announces plans to go public via SPAC
VintageWineEstatesgoespublic Vintage Wine Estates (“VWE”) president Terry Wheatley, who is poised to become the first female president of a multi-hundred million dollar wine producer in American history...